Clinical Scorecard: Interactions Between Polysaccharides and Gut Microbiota: Mechanisms Influencing the Immune Microenvironment in Hepatocellular Carcinoma
At a Glance
Category
Detail
Condition
Key Mechanisms
Gut microbiota dysbiosis and polysaccharide interactions
Target Population
Care Setting
Oncology and research settings
Key Highlights
HCC accounts for approximately 90% of primary liver cancers.
Gut microbiota dysbiosis contributes to immunosuppression and HCC progression.
Microbial metabolites influence the hepatic tumor microenvironment through TLR/NF-κB signaling.
Challenges include polysaccharide structural heterogeneity and undefined safe dose windows.
Guideline-Based Recommendations
Diagnosis
Monitor gut microbiota composition in HCC patients.
Management
Consider interventions to modulate gut microbiota.
Monitoring & Follow-up
Assess immune responses and inflammatory markers in HCC patients.
Risks
Potential for chronic inflammation and immune dysregulation due to gut microbiota dysbiosis.
Patient & Prescribing Data
Patients with hepatocellular carcinoma and gut microbiota dysbiosis.
